Matters arising

Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia"

Tyrrell et al recently described 3 patients with progressive loss of speech output combined with pronounced orofacial apraxia.1 Cases 1 and 2 had been symptomatic for only three years and case 2 had had symptoms for six years. In addition to the speech disturbances, case 3 also demonstrated dyspraxia of the limbs as did their case 4 in another recent publication,2 a patient who had been symptomatic for only two years and six months. CT scanning revealed asymmetrical cortical atrophy and PET scans demonstrated profound reduction in frontal lobe metabolism. The authors discussed this clinical entity as it relates to other "focal cortical degenerations" which have a somewhat heterogeneous underlying pathology.

One important clinico-pathological entity that the authors overlooked in their discussion, which I believe may account for one or more of their cases, is cortical-basal ganglionic degeneration (CBGD).3,4 Although our group and others have pointed out that this disorder usually begins with asymmetric limb cortical and/or basal ganglionic dysfunction, I have now seen patients who present with progressive loss of speech output and orofacial apraxia identical to the cases described by Tyrrell et al.5 The delay between the onset of speech symptoms and more typical clinical signs has been as long as five to six years. One such patient, to be reported in greater detail elsewhere, has died recently and pathological confirmation of CBGD has been obtained. This patient was not included in our series of 15 cases of CBGD because at that time his signs and symptoms, which had been present for five years and six months, were restricted to those described in the cases of Tyrrell et al.

Briefly, this 73 year old male developed difficulties pronouncing selected words at the age of 64. This problem slowly progressed over 15 years to the point that it was difficult even for his wife to understand him. Despite his speech problems he had no other complaints. Eating was unimpaired and he maintained an active exercise programme comprised of swimming, cross-country skiing and walking. At the age of 69, when I first saw him, he demonstrated markedly impaired speech and almost all words were unintelligible. The mouth was held open much of the time. There was severe apraxia for all movements of the lower face and tongue. He had occasional but inconsistent difficulty performing or maintaining eyelid closure and eccentric gaze. There was no ability to suppress blinking in response to glabellar tap (Meyerson’s sign), an easily elicitable jaw jerk, snout and palatal men brinxes. The remainder of the neurological examination at that time was entirely normal. Investigations were unrevealing and PET scanning using both 6[F] fluoro-Levedopa and [18F] fluoro-deoxyglucose was essentially normal.

Over the next four and a half years he became anarthric and other bulbar functions became involved, eventually necessitating feeding gastrostomy. He developed stimulus sensitive myoclonus of the right side of the face only and a severe akinetic-rigid syndrome with pronounced limb apraxias resulting in him becoming bedbound and unable to care for himself. He died of aspiration pneumonia. Pathological assessment revealed the classic changes of CBGD.

Our preliminary PET results using fluorodopa, tyrosine, and 18F as used by Tyrrell et al indicate that bifrontal hypometabolism is not a universal feature of patients presenting with progressive loss of speech output and orofacial dyspraxia. The changes described by Tyrrell et al were most marked in the inferior and lateral portions of the frontal lobes with some extension into the parietal and temporal cortices. It will be interesting to determine if the early presence of these changes predict the subsequent course, and even underlying pathological disturbances, if more than one disease state can result in the same clinical picture. However, clinico-pathological correlation studies will be required in a number of similar patients before this can be resolved. Posterior frontal hypometabolism (again using 18F) as described by Sawle et al in CBGD was also absent in my patient at a time that his symptoms were limited to cranial structures. This indicates that the pattern of disturbances found by Sawle et al cannot be used as a diagnostic marker for this disorder at all stages of development. The failure of fluorodopa scans to demonstrate definite clinical evidence of nigral dopaminergic pathology, which to date has been invariably present in CBGD, is extremely disappointing. 18F-dopa scans were done at a time when we were not able to quantify 18F uptake. For this reason it is impossible to exclude a mild but significant generalised and symmetrical reduction in striatal accumulation. However, the prominent reductions found by Sawle et al, which were strikingly asymmetrical, were not seen. Further quantified analyses will be required in CBGD patients with isolated speech disturbances before this issue is resolved. Our results indicate that 18F-dopa PET scanning may not be a reliable marker of this disorder in its earliest stage. Unfortunately, no other diagnostic or predictive tests are available in CBGD and brain biopsy usually fails to reveal the classic pathological changes. The lack of striatal dopaminergic changes in this patient may suggest that nigral degeneration may be a later developing and rapidly progressive feature in some CBGD patients. This contrasts with the slowly progressive, prolonged pre-clinical nigral degeneration proposed in idiopathic Parkinson’s disease when 18F-dopa scanning might serve as a more reliable marker of very early disease.

The clinico-pathological experience described here emphasises the need for caution and restraint in reporting patients at a relatively early stage in the course of a progressive "degenerative" disorder. It will be extremely important for Tyrrell and colleagues to provide a follow-up report on the course of their patients over subsequent years.


ROSSER MN
T TYRRELL
Department of Neurology,
St Mary’s Hospital,
London W1, UK


Recent Advances in Psychogeriatrics—2.
Edited by TOM ARRIE (Py 224; Price: £29.95).

It has been seven years since the first Recent Advances in Psychogeriatrics. A new volume is timely as there have been significant scientific advances and the roles of the social

BOOK REVIEWS

All titles reviewed here are available from the BMJ Bookshop, PO Box 295, London WC1H 9TE. Prices include postage in the United Kingdom and for members of the British Forces Overseas, but overseas customers should add £2 per item for postage and packing. Payment can be made by cheque in sterling drawn on a United King dom bank, or by credit card (Mastercard, Visa, Access Express) when quoting card number, expiry date, and your full name.
MATTERS ARISING: Rossor and Tyrrell reply;

MN Rosser and P Tyrrell

*J Neural Neurosurg Psychiatry* 1992 55: 1101
doi: 10.1136/jnnp.55.11.1101-a

Updated information and services can be found at:
http://jnnp.bmj.com/content/55/11/1101.2.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/